In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Italy establishes healthcare R&D (research and development) commission:

This article was originally published in Clinica

Executive Summary

Italy has established the national healthcare R&D commission. The ultimate aim of the Commissione nazionale della Ricerca Sanitaria (CNRS) is to provide a practical link between national research activities and regional healthcare delivery policies. It will establish research projects in line with national healthcare priorities, and monitor and analyse peer-reviewed data more widely, with a view to broadcasting the implications that emerge from these, according to the health ministry. As such, its activities should, says the ministry, directly influence the delivery of the national healthcare programme. The commission comprises 30 members, equally representing the central government and the collective of regional healthcare authorities (Conferenza Stato Regioni); it is chaired by health minister Livia Turco.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT049721

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel